ABLYNX Strengthens Management Team with the Appointment of Dr Debbie Law as Chief Scientific Officer - Gilde Healthcare

ABLYNX Strengthens Management Team with the Appointment of Dr Debbie Law as Chief Scientific Officer

7 januari 2009

GHENT, Belgium – Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that it has appointed Dr Debbie Law, as its Chief Scientific Officer.

Dr Law has over thirteen years experience in the biotech industry, with significant expertise in drug discovery and the successful progression of lead candidates into preclinical development. She will head up the research activities and identify and prioritise new therapeutic programmes that Ablynx will take forward to continue building its rapidly growing portfolio of Nanobody® development candidates.

Prior to joining Ablynx, Dr Law was at PDL BioPharma for five years where since 2006 she held the position of Vice President of Research. Previously she has also held senior research positions with EOS Biotechnology and COR Therapeutics.

Dr Law received her D. Phil. in immunology from the University Oxford in 1989 and followed this taking a post-doctoral position at the University of California, San Francisco.

Dr Edwin Moses, CEO and Chairman said: “We are delighted that Debbie is joining to head up the research activities at Ablynx. She brings with her a wealth of knowledge and experience in the drug discovery area with particularly strong expertise in biologics, which will further strengthen and complement our existing management team. We continue to rapidly advance our lead candidates towards the clinic and currently have two of our own Nanobodies® in clinical trials.”

Commenting on her appointment, Dr Law said: “I am joining Ablynx at a tremendously exciting time and I am looking forward to contribute to the creation of a very strong Nanobody® portfolio of products. I am impressed by the broad applicability of the Nanobody® technology to different target classes and therapeutic areas. I am also excited by the possibility of advancing alternative routes of delivery of Nanobodies®.”

-ends-

For more information, please contact:

College Hill Life Sciences for UK/International media enquiries:
Sue Charles, Justine Lamond,
Dr John McIntyre
t:   +44 (0)20 7866 7857
e:  ablynx@collegehill.com

Ablynx:

Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / 
     +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com

Eva-Lotta Allan
Chief Business Officer
t:   +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / 
     +44 (0)7990 570 900
e:  eva-lotta.allan@ablynx.com

Complete version of the press release in English [PDF]

Visit our website: www.ablynx.com

Meer nieuws

Boston Scientific to Acquire Nalu Medical

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation....
17 oktober 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
15 oktober 2025

Gilde Healthcare company SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual...
14 oktober 2025